Press release
Molecular Pharming Solution Launches Rapid Plant-Based Recombinant Protein Production Service
Molecular Pharming Solution
The service provides research-grade recombinant proteins delivered in significantly shorter timelines than traditional mammalian or microbial platforms. MPS's plant-based expression technology enables rapid scale-up, high flexibility, and reduced production costs, making it ideal for early-stage R&D, feasibility studies, and assay development.
"Many innovators face long lead times and high costs when outsourcing recombinant protein production. Our platform helps remove those barriers," said a spokesperson for Molecular Pharming Solution. "This service was built specifically for startups and small research teams who need high-quality proteins quickly and efficiently."
In addition to expression services, MPS offers QC testing, method development, and QMS support for teams preparing for downstream scale-up or future cGMP production. The new service provides an accelerated and reliable path from early discovery through advanced development stages.
For inquiries or project discussions, visit: www.molecularpharm.com
Molecular Pharming Solution
Chulalongkorn University, 254 Chulapat 14 Building, M floor, Phaya Thai Rd, Wang Mai, Pathum Wan, Bangkok 10330, Thailand
Molecular Pharming Solution (MPS), a subsidiary of Baiya Phytopharm Co., Ltd., specializes in plant-based recombinant protein production, QC method development, cGMP manufacturing, and regulatory support services for biopharmaceutical innovators. MPS works with biotech startups, academic laboratories, diagnostics developers, and small-to-mid-sized pharmaceutical companies to deliver fast, flexible, and cost-effective biologics development solutions. With advanced plant molecular farming technology and an experienced quality and production team, MPS helps partners accelerate timelines, reduce costs, and transform early-stage research into real-world therapeutic and diagnostic products.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Molecular Pharming Solution Launches Rapid Plant-Based Recombinant Protein Production Service here
News-ID: 4292824 • Views: …
More Releases for MPS
Mucopolysaccharidosis I (MPS I) Market Emerging Trends and Growth Prospects 2034
Introduction
Mucopolysaccharidosis I (MPS I) is a rare lysosomal storage disorder caused by the deficiency of the enzyme α-L-iduronidase, leading to progressive multisystemic complications including skeletal deformities, organ dysfunction, and neurological decline in severe cases. The disease is categorized into Hurler, Hurler-Scheie, and Scheie syndromes, each varying in severity.
Over the past two decades, the availability of enzyme replacement therapy (ERT) has significantly improved patient outcomes, while hematopoietic stem cell transplantation (HSCT)…
Modular Panelboard System (MPS) Market 2022 | Detailed Report
Global Modular Panelboard System (MPS) Market 2021-2027, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. An exclusive data offered in this report is collected by research and industry experts team.
Download FREE Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5256552
The report…
Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) Therapeutics - Pipelin …
Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a progressive disorder that primarily affects brain and spinal cord (central nervous system). People with MPS III generally do not display features at birth, but they begin to show signs and symptoms of this disorder during early childhood. Affected children often initially have delayed speech and behaviour problems.
Download the sample report @ https://www.pharmaproff.com/request-sample/1146
In later stages of this disorder, people…
Managed Print Services (MPS) Market Experience A Tremendous growth in future
HTF MI recently introduced Global Managed Print Services (MPS) Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are Xerox Corporation, HP, Canon, Ricoh, Lexmark, Konica Minolta Inc.,…
ROTOCONTROL Appoints MPS Systems UK as Agent in United Kingdom
Trittau, Germany (July 18, 2013) – ROTOCONTROL, a manufacturer of leading-edge slitter/rewinder inspection machines today announced the appointment of MPS Systems UK as the ROTOCONTROL/LeoMat agent in the United Kingdom. MPS Systems UK, a subsidiary of the Dutch MPS Systems B.V., will now offer the ROTOCONTROL/LeoMat brand of leading-edge finishing machines for inspection, slitting, rewinding, die cutting, overprinting, digital labels and booklet labels for converters throughout the United Kingdom.
Led by…
Data8 to offer unlimited TPS, CTPS and MPS screening licences
Data8, the premier data enrichment specialist, have today announced that they will offer unlimited licenses to large volume TPS (Telephone Preference Service), CTPS (Corporate Telephone Preference Service) and MPS (Mail Preference Service) users. By removing the royalty fee structure, data8 believe it will encourage wide spread adoption by clients of these data files.
Antony Allen, managing director data8, “I am pleased to announce today that from 1st February 2012 we…
